Cyclerion Therapeutics (CYCN) Return on Sales (2019 - 2025)
Historic Return on Sales for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to 1.15%.
- Cyclerion Therapeutics' Return on Sales rose 143200.0% to 1.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.45%, marking a year-over-year increase of 140300.0%. This contributed to the annual value of 86.98% for FY2022, which is 729700.0% down from last year.
- According to the latest figures from Q3 2025, Cyclerion Therapeutics' Return on Sales is 1.15%, which was up 143200.0% from 17.98% recorded in Q2 2025.
- Cyclerion Therapeutics' Return on Sales' 5-year high stood at 1.15% during Q3 2025, with a 5-year trough of 216.05% in Q1 2021.
- Its 5-year average for Return on Sales is 39.88%, with a median of 22.58% in 2021.
- As far as peak fluctuations go, Cyclerion Therapeutics' Return on Sales tumbled by -1961000bps in 2021, and later skyrocketed by 1977900bps in 2022.
- Cyclerion Therapeutics' Return on Sales (Quarter) stood at 26.9% in 2021, then fell by -29bps to 34.81% in 2022, then crashed by -177bps to 96.26% in 2023, then skyrocketed by 98bps to 1.5% in 2024, then rose by 23bps to 1.15% in 2025.
- Its last three reported values are 1.15% in Q3 2025, 17.98% for Q2 2025, and 17.99% during Q1 2025.